TRDA (Entrada Therapeutics) Dividends per Share: $0.00 (TTM As of Mar. 2026)


TRDA Entrada Therapeutics Inc TRDA
26 GF Score
Price $7.45
GF Value $0.98
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Entrada Therapeutics Dividends per Share?

Entrada Therapeutics TRDA -1.06% 26 Dividends per Share is $0.00 as of Mar. 2026. GuruFocus rates TRDA with a GF Score™ of 26/100 and a GF Value™ of $0.98 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Entrada Therapeutics's dividends per share for the three months ended in Mar. 2026 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Its Dividend Payout Ratio for the three months ended in Mar. 2026 was 0.00. As of today, Entrada Therapeutics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Entrada Therapeutics  (NAS:TRDA) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Entrada Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -0.95
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entrada Therapeutics Dividends per Share Related Terms

Entrada Therapeutics Dividends per Share Historical Data

* Premium members only.

The historical data trend for Entrada Therapeutics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entrada Therapeutics Dividends per Share Chart

Entrada Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends per Share
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Entrada Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividends per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TRDA vs NMRA, MGNX, CNXU: Dividends per Share Comparison

For the Biotechnology subindustry, Entrada Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Dividend Yield % falls into.


TRDA
26GF Score
Entrada Therapeutics Inc TRDA
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entrada Therapeutics Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of $0.00 mean?
Entrada Therapeutics (TRDA) has a Dividends per Share of $0.00 as of Mar. 2026. Dividends per share represents the per-share amount paid as dividends. View historical data on Entrada Therapeutics and its competitors.
Is Entrada Therapeutics' Dividends per Share too high?
Entrada Therapeutics' current Dividends per Share is $0.00. Overall, Entrada Therapeutics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Dividends per Share compare to NMRA and MGNX?
Entrada Therapeutics' Dividends per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Entrada Therapeutics and its competitors. Entrada Therapeutics's current Dividends per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.98, compared to a current price of $7.45 — trading 660.2% above its estimated fair value. The current Dividends per Share is $0.00. Entrada Therapeutics' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Dividends per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.45 is trading 660.2% above its estimated GF Value™ of $0.98. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

  • Dividends per Share: $0.00
  • GF Value™: $0.98 vs. price of $7.45 (660.2% above fair value)
  • GF Score™: 26/100 with 4 warning signs

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
26GF Score

Get the complete analysis for TRDA

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price
$0.98
GF Value